Sadikov N., Xu Chao Yue, Odilov B., Xin Zhi Hong, Zhang Zhao Нua

Email: Sadikov6107@scientifictext.ru

Sadikov Nematullo - Master Degree Student;

Xu Chao Yue - Master Degree Student,

PEDIATRICS FACULTY;

Odilov Bekzod - Master Degree student,

FACULTY OF ENDOCRINOLOGY;

Xin Zhi Hong - Master Degree Student,

PEDIATRICS FACULTY,

SHANDONG UNIVERSITY;

Zhang Zhao Hua – Professor,

PEDIATRICS FACULTY,

SHANDONG UNIVERSITY,

Pediatr,

HOSPITAL № 2,

JINAN, SHANDONG PROVINCE, PEOPLE'S REPUBLIC OF CHINA

Abstract: сommunity-acquired Pneumonia (CAP) is an infection of the lung parenchyma that is acquired outside of  hospital,[1] involved approximately 150 million new cases annually, among children younger than 5 years old worldwide. We retrospectively evaluated the effect of Prednisolone in 89 children with CAP who were admitted to the 2^nd hospital of Shandong University (China) and Infectious diseases of Andijon region (Uzbekistan).  The mean age was 6.3 in China (Placebo) and 9.3 in Uzbekistan (control) years, 54% and 52% of them were boys respectively. All children had received broad spectrum antibiotics (cephalosporin) or Macrolides (Azithromycin) and Oxygen. In addition to these we added Prednisolone 1 mg/kg on day 2 of admission to control group. 24 (68.5% from all febrile) children were became afebrile within 24 hours after Predisolone use on day 3 of admission, and their clinical status developed in control group, when it was achieved on day 7 in Placebo group. Hospital days also shortened in control group (6 days) than placebo (8 days) (p value ≤ 0.01). In conclusion, steroid therapy helpful for reducing hospital stay and morbidity in children with community-acquired Pneumonia and no observed side effects.

Keywords: рrednisolone, pediatric pneumonia, hospital day, placebo, corticosteroid, hospitalization, temperature, cough, morbidity.

ЭФФЕКТИВНОСТЬ ПРЕДНИЗОЛОНА У ДЕТЕЙ С ВНЕБОЛЬНИЧНОЙ ПНЕВМОНИЕЙ

Садиков Н., Шу Чао Юе, Одилов Б., Шин Жи Хонг, Жанг Жао Хуа

Садиков Неъматулло – магистрант;

Шу Чао Юе – магистрант,

факультет педиатрии;

Одилов Бекзод – магистрант,

факультет эндокринологии

Шин Жи Хонг – магистрант,

факультет педиатрии,

Шандонский университет,

Жанг Жао Хуа – профессор,

факультет педиатрии,

Шандонский университет,

педиатр,

больница № 2,

г. Джинан, провинция Шандонг, Китайская Народная Республика

Аннотация: внебольничная пневмония - это инфекция легочной паренхимы, приобретенной вне медицинских учреждений. Во всем мире ежегодно встречается примерно 150 миллионов новых случаев у детей младше 5 лет. Мы ретроспективно исследовали 89 детей с внебольничной пневмонией, положенных во вторую больницу Шандонского университета (Китай) и Андижанскую областную инфекционную больницу. Средний возраст больных в группе плацебо (в Китае) был 6.3, в контрольной группе (в Андижане) равнялся 9.3 лет жизни. 54% процентов из 46 составили мальчики в группе плацебо, почти такое соотношение (52%) на контрольной группе. Все дети приняли антибиотики (цефалоспорины или азитромицин) и Кислород. Дополнительно к ним мы назначали Преднизолон (1 мг/кг) детям, находящимся в Андижане, со второго дня на больничной койке. У 68.5% детей с повышенной температурой тела улучшилась их температура после принятия  преднизолона уже через 24 часа и клинический статус тоже улучшился в контрольной группе. В плацебо группе мы пришли к этому результату на седьмой день госпитализации. Больничные дни тоже стали меньше в контрольной группе, чем в плацебо (6 дней к 8, p value ≤ 0.01). В заключение я хотел бы сказать: кортикостероидная терапия помогла уменьшить больничные дни, заболеваемость и смертность у детей с внебольничной пневмонией, без обнаружения ярко выраженных побочных эффектов.

Ключевые слова: преднизолон, пневмония, плацебо, температура, кортикостероид.

References / Список литературы

• Grief S.N. & Loza J.K. Guidelines for the Evaluation and Treatment of Pneumonia. Care - Clin. Off. Pract. 45, 485–503 (2018).
• Lodha R., Kabra S.K. & Pandey R.M. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst. Rev. 2013 (2013).
• Harris M. et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: Update 2011. Thorax 66 (2011).
• Liu L. et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: An updated systematic analysis. Lancet 385. 430–440 (2015).
• Brar N.K. & Niederman M.S. Management of community-acquired pneumonia: A review and update. Adv. Respir. Dis. 5, 61–78 (2011).
• Nascimento-Carvalho C.M. Community-acquired pneumonia among children: the latest evidence for an updated management. Pediatr. (Rio. J). 96, 29–38 (2020).
• Ostermann H. et al. Resource use by patients hospitalized with community-acquired pneumonia in Europe: Analysis of the REACH study. BMC Pulm. Med. 14, (2014).
• Sabry N.A. & Omar E.E.-D. Corticosteroids and ICU Course of Community Acquired Pneumonia in Egyptian Settings. & Pharm. 02, 73–81 (2011).
• Confalonieri M. et al. Hydrocortisone infusion for severe community-acquired pneumonia: A preliminary randomized study. J. Respir. Crit. Care Med. 171, 242–248 (2005).
• Mikami K. et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 185, 249–255 (2007).
• Meijvis S.C.A. et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: A randomised, double-blind, placebo-controlled trial. Lancet 377, 2023–2030 (2011).
• Torres A. et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial. JAMA - J. Am. Med. Assoc. 313, 677–686 (2015).
• Snijders D., Daniels J.M.A., De Graaff C.S., Van Der Werf T.S. & Boersma W.G. Efficacy of corticosteroids in community-acquired pneumonia: A randomized double-blinded clinical trial. J. Respir. Crit. Care Med. 181, 975–982 (2010).
• Annane D. Corticosteroids and pneumonia: Time to change practice. Lancet 385, 1484–1485 (2015).
• Stern A. et al. Corticosteroids for pneumonia. Cochrane Database Syst. Rev. 2017, (2017).
• Blum C.A. et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: A multicentre, double-blind, randomised, placebo-controlled trial. Lancet 385, 1511–1518 (2015).
• Yuanjing C., Pu H. & Wu T. Corticosteroids for pneumonia. Cochrane Database Syst. Rev. (2009) doi:10.1002/14651858.CD007720.
• Siemieniuk R.A.C. et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: A systematic review and metaanalysis. Intern. Med. 163, 519–528 (2015).
• Tagarro A. et al. Dexamethasone for Parapneumonic Pleural Effusion: A Randomized, Double-Blind, Clinical Trial. Pediatr. 185, 117-123.e6 (2017).
• Nagy B. et al. Efficacy of methylprednisolone in children with severe community acquired pneumonia. Pulmonol. 48, 168–175 (2013).
• Nascimento-Carvalho A.C. & Nascimento-Carvalho C.M. Clinical management of community-acquired pneumonia in young children. Expert Opin. Pharmacother. 20, 435–442 (2019).
• Radisic M., Torn A., Gutierrez P., Defranchi H.A. & Pardo P. Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin. Infect. Dis. an Off. Publ. Infect. Dis. Soc. Am. 31, 1507–1511 (2000).
• Tarp B., Jensen J.S., Østergaard L. & Andersen P.L. Search for agents causing atypical pneumonia in HIV-positive patients by inhibitor-controlled PCR assays. Respir. J. 13, 175–179 (1999).
• Foy H.M. et al. Mycoplasma pneumoniae Infections in Patients with Immunodeficiency Syndromes : Report of Four Cases Published by : Oxford University Press Stable URL : http://www.jstor.org/stable/30108708 Mycoplasma pneumoniae Infections in Patients with Immunodeficiency. 127, 388–393 (2017).
• Denny F.W., Taylor-Robinson D. & Allison A.C. The role of thymus-dependent immunity in Mycoplasma pulmonis infections of mice. Med. Microbiol. 5, 327–336 (1972).
• Tanaka H., Honma S.I., Abe S. & Tamura H. Effects of interleukin-2 and cyclosporin A on pathologic features in Mycoplasma pneumonia. J. Respir. Crit. Care Med. 154, 1908–1912 (1996).
• Tanaka H. et al. [Therapeutic effectiveness of prednisolone in Mycoplasma pulmonis-infected pneumonia in mice]. Nihon Kyobu Shikkan Gakkai Zasshi 32, 42–47 (1994).
• Tanaka H., Koba H., Honma S., Sugaya F. & Abe S. Relationships between radiological pattern and cell-mediated immune response in Mycoplasma pneumoniae pneumonia. Respir. J. 9, 669–672 (1996).
• Taylor G. Immunity to mycoplasma infections of the respiratory tract: A review. R. Soc. Med. 72, 520–526 (1979).
• Opitz O., Pietsch K., Ehlers S. & Jacobs E. Cytokine gene expression in immune mice reinfected with Mycoplasma pneumoniae: The role of T cell subsets in aggravating the inflammatory response. Immunobiology 196, 575–587 (1997).
• Lee K.Y. et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. in Pediatric Pulmonology vol. 41 263–268 (2006).
• Youn Y.S. et al. Early additional immune-modulators for Mycoplasma pneumoniae pneumonia in children: An observation study. Chemother. 46, 239–247 (2014).
• Liverani E., Banerjee S., Roberts W., Naseem K.M. & Perretti M. Prednisolone exerts exquisite inhibitory properties on platelet functions. Pharmacol. 83, 1364–1373 (2012).
• You S.Y., Jwa H.J., Yang E.A., Kil H.R. & Lee J.H. Effects of methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children. Allergy, Asthma Immunol. Res. 6, 22–26 (2014).
• Tashiro M. et al. Adjunctive corticosteroid therapy for inpatients with Mycoplasma pneumoniae pneumonia. BMC Pulm. Med. 17, 1–10 (2017).
• Bajantri B., Venkatram S. & Diaz-Fuentes G. Mycoplasma pneumoniae : A Potentially Severe Infection . Clin. Med. Res. 10, 535–544 (2018).

 

Ссылка для цитирования данной статьи

		Тип лицензии на данную статью – CC BY 4.0. Это значит, что Вы можете свободно цитировать данную статью на любом носителе и в любом формате при указании авторства.
Электронная версия. Sadikov N., Xu Chao Yue, Odilov B., Xin Zhi Hong, Zhang Zhao Нua THE EFFECTIVENESS OF USING PREDNISOLONE IN CHILDREN WITH COMMUNITY–ACQUIRED PNEUMONIA // Вестник науки и образования № 4(107), 2021 [Электронныйресурс].URL: http://scientificjournal.ru/images/PDF/2021/107/the-effectiveness-of-usi.pdf (Дата обращения:ХХ.ХХ.201Х). Печатная версия. Sadikov N., Xu Chao Yue, Odilov B., Xin Zhi Hong, Zhang Zhao Нua THE EFFECTIVENESS OF USING PREDNISOLONE IN CHILDREN WITH COMMUNITY–ACQUIRED PNEUMONIA // Вестник науки и образования № 4(107), 2021, C. {см. журнал}.

Поделитесь данной статьей, повысьте свой научный статус в социальных сетях

Tweet